Aptose Biosciences Links With National Cancer Institute to Develop Tuspetinib in MyeloMATCH Trials
Aptose Biosciences Links With National Cancer Institute to Develop Tuspetinib in MyeloMATCH Trials
aptose biosciences與國家癌症研究所合作，在MyeloMATCH試驗中開發Tuspetinib
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間